AR100132A1 - Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino - Google Patents
Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femeninoInfo
- Publication number
- AR100132A1 AR100132A1 ARP150101170A ARP150101170A AR100132A1 AR 100132 A1 AR100132 A1 AR 100132A1 AR P150101170 A ARP150101170 A AR P150101170A AR P150101170 A ARP150101170 A AR P150101170A AR 100132 A1 AR100132 A1 AR 100132A1
- Authority
- AR
- Argentina
- Prior art keywords
- female subject
- fsh
- preparation
- stimulate
- development
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
- A61B17/43—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for artificial insemination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un método para la hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino, que comprende (a) administrar a un sujeto femenino una preparación de FSH recombinante utilizando un régimen de dosificación en donde las dosis individuales suman hasta una cantidad promedio de aproximadamente 35 a aproximadamente 250 UI de FSH por día; (b) activar la ovulación cuando hay múltiples folículos con un diámetro medio igual a o mayor que 12 mm. y/o cuando hay al menos un folículo con un diámetro de al menos 17 mm.; (c) obtener múltiples ovocitos del sujeto femenino, en donde en promedio se obtienen al menos 5 ovocitos por sujeto femenino y/o se obtienen al menos 5 ovocitos del sujeto femenino; en donde la FSH recombinante en la preparación tiene un patrón de glicosilación que comprende las siguientes características: (i) una cantidad relativa de glicanos que portan N-acetilglucosamina de bisección (bisGlcNAc) de al menos 20% de todos los glicanos unidos a la FSH en la preparación; y (ii) una cantidad relativa de ácido siálico en enlace 2,6 de al menos 40% de todos los residuos de ácido siálico unidos a la FSH en la preparación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461981621P | 2014-04-18 | 2014-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100132A1 true AR100132A1 (es) | 2016-09-14 |
Family
ID=53015773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101170A AR100132A1 (es) | 2014-04-18 | 2015-04-17 | Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170035854A1 (es) |
| EP (1) | EP3131571A1 (es) |
| JP (1) | JP2017513853A (es) |
| KR (1) | KR20160144480A (es) |
| CN (1) | CN106413735A (es) |
| AR (1) | AR100132A1 (es) |
| AU (1) | AU2015248793A1 (es) |
| BR (1) | BR112016023668A2 (es) |
| CA (1) | CA2945883A1 (es) |
| IL (1) | IL248362A0 (es) |
| MX (1) | MX2016013449A (es) |
| SG (1) | SG11201608132UA (es) |
| WO (1) | WO2015158875A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| WO2018080120A1 (en) * | 2016-10-28 | 2018-05-03 | Samsung Electronics Co., Ltd. | Method and apparatus for follicular quantification in 3d ultrasound images |
| ES2904787T3 (es) * | 2017-09-01 | 2022-04-06 | Ferring Bv | Composición para la estimulación ovárica controlada |
| CN110570952B (zh) * | 2018-06-05 | 2022-04-12 | 北京大学第三医院 | 预测拮抗剂方案下受试者卵巢低反应概率的系统及指导促性腺激素起始用药剂量选择的系统 |
| CN112603990B (zh) * | 2020-12-17 | 2022-03-08 | 广州医药研究总院有限公司 | 提高犬卵巢卵丘-卵母细胞复合体数量的试剂盒及其应用 |
| US20240285250A1 (en) * | 2023-02-23 | 2024-08-29 | Urmila Diwekar | Systems and Methods for Personalized Medicine in IVF for Reduced Dosage and Testing, and Better Outcomes |
| CN116798634B (zh) * | 2023-08-25 | 2023-11-21 | 北京大学深圳医院 | 一种fsh启动剂量预测系统、电子设备及存储介质 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MEP38608A (en) | 2001-10-22 | 2011-02-10 | Merck Serono Sa | Gonadotrophins for folliculogenesis |
| KR101545914B1 (ko) * | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
| EP2325194A1 (en) | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
| WO2012016576A1 (en) | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
-
2015
- 2015-04-17 BR BR112016023668A patent/BR112016023668A2/pt not_active Application Discontinuation
- 2015-04-17 JP JP2016562890A patent/JP2017513853A/ja active Pending
- 2015-04-17 AU AU2015248793A patent/AU2015248793A1/en not_active Abandoned
- 2015-04-17 WO PCT/EP2015/058352 patent/WO2015158875A1/en active Application Filing
- 2015-04-17 AR ARP150101170A patent/AR100132A1/es unknown
- 2015-04-17 US US15/303,703 patent/US20170035854A1/en not_active Abandoned
- 2015-04-17 EP EP15719165.1A patent/EP3131571A1/en not_active Withdrawn
- 2015-04-17 MX MX2016013449A patent/MX2016013449A/es unknown
- 2015-04-17 KR KR1020167031711A patent/KR20160144480A/ko unknown
- 2015-04-17 CN CN201580020167.7A patent/CN106413735A/zh active Pending
- 2015-04-17 CA CA2945883A patent/CA2945883A1/en not_active Abandoned
- 2015-04-17 SG SG11201608132UA patent/SG11201608132UA/en unknown
-
2016
- 2016-10-13 IL IL248362A patent/IL248362A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20170035854A1 (en) | 2017-02-09 |
| AU2015248793A1 (en) | 2016-11-03 |
| EP3131571A1 (en) | 2017-02-22 |
| IL248362A0 (en) | 2016-11-30 |
| BR112016023668A2 (pt) | 2017-10-17 |
| CA2945883A1 (en) | 2015-10-22 |
| MX2016013449A (es) | 2017-05-04 |
| WO2015158875A1 (en) | 2015-10-22 |
| SG11201608132UA (en) | 2016-11-29 |
| KR20160144480A (ko) | 2016-12-16 |
| CN106413735A (zh) | 2017-02-15 |
| JP2017513853A (ja) | 2017-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100132A1 (es) | Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino | |
| BR112018001015A2 (pt) | dispositivo e método para conectar regiões de porta separadas usando um corte de porta | |
| PE20181531A1 (es) | Vacuna del virus herpes simple | |
| CL2017001089A1 (es) | Vacunas terapéuticas contra el vph16 | |
| ECSP17059343A (es) | ARNi VARIANTE | |
| MX2020004005A (es) | Terapias genicas para los trastornos lisosomales. | |
| UY36870A (es) | Análogos de insulina novedosos | |
| CL2015003346A1 (es) | Composiciones de cenicriviroc y métodos para realizarlas y utilizarlas | |
| PE20181338A1 (es) | Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden | |
| EP4364767A3 (en) | Sub-assembly of a medicament delivery device and a medicament delivery device | |
| WO2015106269A8 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| BR112017015310A2 (pt) | uso de pgr4 como um agente anti-inflamatório | |
| UY37505A (es) | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico | |
| MX2016008979A (es) | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. | |
| BR112016013485A2 (pt) | Método para preparar um produto lácteo tendo teor estável de galacto-oligossacarídeo(s) | |
| PL412337A1 (pl) | Wziernik nosowy | |
| CL2017000053A1 (es) | Anticuerpos de unión a protofibrillas aß | |
| CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
| MX2020006588A (es) | Composiciones de pienso animal y usos de las mismas. | |
| DOP2018000057A (es) | Composiciones biofarmacéuticas | |
| CY1124734T1 (el) | Μορφες δοσολογιας αυξητικης ορμονικης μακρας δρασης | |
| MX2017009812A (es) | Composiciones y metodos para inhibir infeccion viral. | |
| BR112018011851A2 (pt) | compostos de isoindol | |
| BR112017013574A2 (pt) | conjugados de aminoácido e peptídeo e usos dos mesmos | |
| EA201691860A1 (ru) | Пептидный медикамент в виде сухого порошка |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |